| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer
|
Blumenthal, G.M.
|
|
|
30 |
5 |
p. 830-838
|
article
|
| 2 |
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population
|
Turner, N.C.
|
|
|
30 |
5 |
p. 774-780
|
article
|
| 3 |
Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial
|
Kim, S.T.
|
|
|
30 |
5 |
p. 788-795
|
article
|
| 4 |
Circulating driver gene mutations: what is the impact on melanoma patients’ management?
|
Palmieri, G.
|
|
|
30 |
5 |
p. 669-671
|
article
|
| 5 |
Communication training in oncology needs a theoretical framework
|
Salander, P.
|
|
|
30 |
5 |
p. 853
|
article
|
| 6 |
Correction to: “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
|
Vogel, A.
|
|
|
30 |
5 |
p. 871-873
|
article
|
| 7 |
Correction to: “Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
|
Planchard, D.
|
|
|
30 |
5 |
p. 863-870
|
article
|
| 8 |
Correction to: “Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer”
|
Ricordel, C.
|
|
|
30 |
5 |
p. 858
|
article
|
| 9 |
Correction to: “Safety and dose modification for patients receiving niraparib”
|
Berek, J.S.
|
|
|
30 |
5 |
p. 859
|
article
|
| 10 |
Correction to: “Waldenström’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
|
Kastritis, E.
|
|
|
30 |
5 |
p. 860-862
|
article
|
| 11 |
Editorial board
|
|
|
|
30 |
5 |
p. ii-iii
|
article
|
| 12 |
Enthuse for PERUSE: when clinical judgment overcomes regulatory boundaries
|
Guarneri, V.
|
|
|
30 |
5 |
p. 665-667
|
article
|
| 13 |
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease † † These consensus statements were developed by the European Society for Medical Oncology (ESMO) and the European Society of Gynaecological Oncology (ESGO) and are published jointly in the Annals of Oncology and the International Journal of Gynecological Cancer. The two societies nominated participants who attended the consensus conference and co-authored the final manuscript.
|
Colombo, N.
|
|
|
30 |
5 |
p. 672-705
|
article
|
| 14 |
European cancer mortality predictions for the year 2019 with focus on breast cancer
|
Malvezzi, M.
|
|
|
30 |
5 |
p. 781-787
|
article
|
| 15 |
Head and neck cancer prevention: from primary prevention to impact of clinicians on reducing burden
|
Hashim, D.
|
|
|
30 |
5 |
p. 744-756
|
article
|
| 16 |
Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study
|
Joly, F.
|
|
|
30 |
5 |
p. 845-852
|
article
|
| 17 |
Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial
|
Trédan, O.
|
|
|
30 |
5 |
p. 757-765
|
article
|
| 18 |
Molecular screening to select therapy for advanced cancer?
|
Tannock, I.F.
|
|
|
30 |
5 |
p. 661-663
|
article
|
| 19 |
Neuronal autoantibodies associated with cognitive impairment in melanoma patients
|
Bartels, F.
|
|
|
30 |
5 |
p. 823-829
|
article
|
| 20 |
Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients
|
van Waalwijk van Doorn-Khosrovani, S.B.
|
|
|
30 |
5 |
p. 663-665
|
article
|
| 21 |
Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial
|
Santos, C.
|
|
|
30 |
5 |
p. 796-803
|
article
|
| 22 |
Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA
|
Tan, L.
|
|
|
30 |
5 |
p. 804-814
|
article
|
| 23 |
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
|
Bachelot, T.
|
|
|
30 |
5 |
p. 766-773
|
article
|
| 24 |
Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients
|
Lee, J.H.
|
|
|
30 |
5 |
p. 815-822
|
article
|
| 25 |
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † † Approved by the ESMO Guidelines Committee: September 2008, last update January 2019. This publication supersedes the previously published version—Ann Oncol 2016; 27 (Suppl 5): v58–v68.
|
Escudier, B.
|
|
|
30 |
5 |
p. 706-720
|
article
|
| 26 |
Reply to ‘Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists’ by Haenssle et al.
|
Oakden-Rayner, L.
|
|
|
30 |
5 |
p. 854
|
article
|
| 27 |
Reply to the letter to the editor ‘Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists’ by H. A. Haenssle et al.
|
Haenssle, H.A.
|
|
|
30 |
5 |
p. 854-857
|
article
|
| 28 |
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
|
Schoenfeld, A.J.
|
|
|
30 |
5 |
p. 839-844
|
article
|
| 29 |
Table of Contents
|
|
|
|
30 |
5 |
p. iv-vi
|
article
|
| 30 |
Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option
|
Buechel, M.
|
|
|
30 |
5 |
p. 721-732
|
article
|
| 31 |
Vitamin D: should public health recommendations also consider cancer outcomes?
|
Naska, A.
|
|
|
30 |
5 |
p. 667-668
|
article
|
| 32 |
Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials
|
Keum, N.
|
|
|
30 |
5 |
p. 733-743
|
article
|
Journal description